159 related articles for article (PubMed ID: 34866312)
1. Dasatinib does not exacerbate dexamethasone-induced osteonecrosis in murine models of acute lymphoblastic leukemia therapy.
Finch ER; Janke LJ; Li L; Payton MA; Jenkins DA; Crews KR; Relling MV; Karol SE
Pediatr Blood Cancer; 2022 Apr; 69(4):e29490. PubMed ID: 34866312
[TBL] [Abstract][Full Text] [Related]
2. Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia.
Ramsey LB; Janke LJ; Payton MA; Cai X; Paugh SW; Karol SE; Kamdem Kamdem L; Cheng C; Williams RT; Jeha S; Pui CH; Evans WE; Relling MV
PLoS One; 2015; 10(8):e0135134. PubMed ID: 26252865
[TBL] [Abstract][Full Text] [Related]
3. Fenofibrate reduces osteonecrosis without affecting antileukemic efficacy in dexamethasone-treated mice.
Finch ER; Payton MA; Jenkins DA; Cai X; Li L; Karol SE; Relling MV; Janke LJ
Haematologica; 2021 Aug; 106(8):2095-2101. PubMed ID: 32675219
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Boulos N; Mulder HL; Calabrese CR; Morrison JB; Rehg JE; Relling MV; Sherr CJ; Williams RT
Blood; 2011 Mar; 117(13):3585-95. PubMed ID: 21263154
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
6. Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models.
Karol SE; Janke LJ; Panetta JC; Ramsey LB; Cai X; Payton MA; Jenkins DA; Evans WE; Relling MV
PLoS One; 2019; 14(5):e0216328. PubMed ID: 31059548
[TBL] [Abstract][Full Text] [Related]
7. Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL.
Appelmann I; Rillahan CD; de Stanchina E; Carbonetti G; Chen C; Lowe SW; Sherr CJ
Blood; 2015 Feb; 125(9):1444-51. PubMed ID: 25499760
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.
Xiao X; Liu P; Li D; Xia Z; Wang P; Zhang X; Liu M; Liao L; Jiao B; Ren R
J Hematol Oncol; 2020 Jun; 13(1):80. PubMed ID: 32552902
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
[TBL] [Abstract][Full Text] [Related]
10. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia.
Fei F; Stoddart S; Müschen M; Kim YM; Groffen J; Heisterkamp N
Leukemia; 2010 Apr; 24(4):813-20. PubMed ID: 20111071
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.
Brattås MK; Reikvam H; Tvedt THA; Bruserud Ø
Expert Opin Investig Drugs; 2019 May; 28(5):411-420. PubMed ID: 30916583
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation.
Takahashi N; Miura M; Scott SA; Niioka T; Sawada K
J Hematol Oncol; 2012 May; 5():23. PubMed ID: 22587422
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Piccaluga PP; Paolini S; Martinelli G
Cancer; 2007 Sep; 110(6):1178-86. PubMed ID: 17701954
[TBL] [Abstract][Full Text] [Related]
14. Bloodstream infections exacerbate incidence and severity of symptomatic glucocorticoid-induced osteonecrosis.
Finch ER; Janke LJ; Smith CA; Karol SE; Pei D; Cheng C; Kaste SC; Inaba H; Pui CH; Wolf J; Relling MV
Pediatr Blood Cancer; 2019 Jun; 66(6):e27669. PubMed ID: 30758124
[TBL] [Abstract][Full Text] [Related]
15. The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patients.
Schubert C; Chatain N; Braunschweig T; Schemionek M; Feldberg K; Hoffmann M; Dufva O; Mustjoki S; Brümmendorf TH; Koschmieder S
Oncotarget; 2017 May; 8(21):34736-34749. PubMed ID: 28423730
[TBL] [Abstract][Full Text] [Related]
16. Impaired dexamethasone-related increase of anticoagulants is associated with the development of osteonecrosis in childhood acute lymphoblastic leukemia.
te Winkel ML; Appel IM; Pieters R; van den Heuvel-Eibrink MM
Haematologica; 2008 Oct; 93(10):1570-4. PubMed ID: 18698082
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.
Benjamini O; Dumlao TL; Kantarjian H; O'Brien S; Garcia-Manero G; Faderl S; Jorgensen J; Luthra R; Garris R; Thomas D; Kebriaei P; Champlin R; Jabbour E; Burger J; Cortes J; Ravandi F
Am J Hematol; 2014 Mar; 89(3):282-7. PubMed ID: 24779033
[TBL] [Abstract][Full Text] [Related]
18. Establishment of a new Philadelphia chromosome-positive acute lymphoblastic leukemia cell line (SK-9) with T315I mutation.
Okabe S; Tauchi T; Ohyashiki K
Exp Hematol; 2010 Sep; 38(9):765-72. PubMed ID: 20471447
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Foà R; Vitale A; Vignetti M; Meloni G; Guarini A; De Propris MS; Elia L; Paoloni F; Fazi P; Cimino G; Nobile F; Ferrara F; Castagnola C; Sica S; Leoni P; Zuffa E; Fozza C; Luppi M; Candoni A; Iacobucci I; Soverini S; Mandelli F; Martinelli G; Baccarani M;
Blood; 2011 Dec; 118(25):6521-8. PubMed ID: 21931113
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL.
Rousselot P; Coudé MM; Gokbuget N; Gambacorti Passerini C; Hayette S; Cayuela JM; Huguet F; Leguay T; Chevallier P; Salanoubat C; Bonmati C; Alexis M; Hunault M; Glaisner S; Agape P; Berthou C; Jourdan E; Fernandes J; Sutton L; Banos A; Reman O; Lioure B; Thomas X; Ifrah N; Lafage-Pochitaloff M; Bornand A; Morisset L; Robin V; Pfeifer H; Delannoy A; Ribera J; Bassan R; Delord M; Hoelzer D; Dombret H; Ottmann OG;
Blood; 2016 Aug; 128(6):774-82. PubMed ID: 27121472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
